REGENXBIO
Latest round
- Series D
Last raised
- May 2015
Total raised
- $98M
Investors
- 8
About REGENXBIO
REGENXBIO Inc.Founded in 2008 in Rockville, US, REGENXBIO Inc. is dedicated to gene therapy development. The founders include Adam Hacking and Patrick Bradley, with Adam Hacking serving as CEO.REGENXBIO focuses on developing innovative gene therapy products aimed at addressing both common and rare diseases through its NAV® Technology Platform. The company’s core product candidates include ABBV-RGX-314, targeting retinal diseases; RGX-202, focused on Duchenne muscular dystrophy; and RGX-121, designed for treating MPS II (Hunter Syndrome). Each of these therapies employs adeno-associated virus (AAV) technology to deliver genetic material into patients' cells, potentially providing one-time curative treatments. The primary end-users of these therapies are patients suffering from the mentioned conditions, as well as their families, with a significant emphasis on improving their quality of life.REGENXBIO's revenue model primarily revolves around partnerships and collaborations with larger pharmaceutical companies, facilitating the development and commercialization of its gene therapy products.REGENXBIO plans to utilize the funds from its 2015 IPO to support the launch of new gene therapy products, enhancing its portfolio. The company aims to expand into international markets, particularly targeting regions in Europe and Asia by 2025.
Who invested in REGENXBIO
8 investors across 2 rounds
See all investors in REGENXBIO
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about REGENXBIO
Who invested in REGENXBIO?
REGENXBIO has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has REGENXBIO raised?
REGENXBIO has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did REGENXBIO last raise money?
REGENXBIO's most recent round on record is a Series D, in May 2015.
What does REGENXBIO do?
REGENXBIO is a biotechnology company.
Where is REGENXBIO headquartered?
REGENXBIO is headquartered in Rockville, US.
Which VCs invest in companies like REGENXBIO?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at REGENXBIO's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like REGENXBIO? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.